| scholarly article | Q13442814 |
| P356 | DOI | 10.3324/HAEMATOL.2013.092155 |
| P8608 | Fatcat ID | release_dhre4dulrzh3vb53oxhepe2rfe |
| P932 | PMC publication ID | 3856961 |
| P698 | PubMed publication ID | 24038026 |
| P5875 | ResearchGate publication ID | 256612626 |
| P50 | author | Azra Raza | Q22957846 |
| William Sun | Q58329734 | ||
| Hagop Kantarjian | Q60394812 | ||
| Srdan Verstovsek | Q64026418 | ||
| Elizabeth O. Hexner | Q85544163 | ||
| Moshe Talpaz | Q87650933 | ||
| Jason Gotlib | Q89931645 | ||
| Murat Osman Arcasoy | Q91476389 | ||
| Ruben Mesa | Q91595991 | ||
| John DiPersio | Q92668323 | ||
| Susan Erickson-Viitanen | Q114428052 | ||
| Kris Vaddi | Q114428053 | ||
| Elliott F Winton | Q117195033 | ||
| Ronald Paquette | Q117195036 | ||
| P2093 | author name string | Vikas Gupta | |
| Richard T Silver | |||
| Victor Sandor | |||
| Michael W N Deininger | |||
| Roger M Lyons | |||
| Richard S Levy | |||
| Carole B Miller | |||
| John V Catalano | |||
| Jimmie H Harvey | |||
| P2860 | cites work | JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 |
| A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 | ||
| Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial | Q33405985 | ||
| Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis | Q33411211 | ||
| Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts | Q33411755 | ||
| Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms | Q36946576 | ||
| Advances in understanding and management of myeloproliferative neoplasms | Q37445395 | ||
| Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond | Q37833893 | ||
| Management of myelofibrosis | Q37967277 | ||
| The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. | Q40463923 | ||
| New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment | Q79802927 | ||
| P433 | issue | 12 | |
| P921 | main subject | myelofibrosis | Q1752571 |
| ruxolitinib | Q7383611 | ||
| P304 | page(s) | 1865-1871 | |
| P577 | publication date | 2013-09-13 | |
| P1433 | published in | Haematologica | Q5638209 |
| P1476 | title | Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. | |
| P478 | volume | 98 |
| Q38945717 | A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence |
| Q36708975 | A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis |
| Q89940664 | Allogeneic hematopoietic stem-cell transplantation for myelofibrosis |
| Q34485103 | CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. |
| Q35689225 | Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib |
| Q26796450 | Clinical potential of pacritinib in the treatment of myelofibrosis |
| Q38695362 | Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation |
| Q42760638 | Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners? |
| Q26996258 | Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis |
| Q54349909 | Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis. |
| Q30315531 | Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thro |
| Q54337792 | Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it? |
| Q64074803 | EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis |
| Q35565555 | Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. |
| Q33436442 | Efficacy and safety of JAK inhibitor ruxolitinib in Chinese patients with myelofibrosis: results of a 1-year follow-up of A2202 |
| Q48062723 | Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis. |
| Q37035925 | Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis. |
| Q33415489 | Efficacy of ruxolitinib for myelofibrosis |
| Q26745939 | Emerging treatment options for myelofibrosis: focus on pacritinib |
| Q38240406 | Epidemiology of MPN: what do we know? |
| Q58797642 | Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study |
| Q36116382 | Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications |
| Q33421876 | Haematological manifestations of lupus |
| Q54357496 | High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms. |
| Q35634902 | Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. |
| Q38260343 | Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia. |
| Q47564349 | Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature |
| Q33411755 | Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts |
| Q54374933 | JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. |
| Q42660823 | JAK inhibitors and myelofibrosis, Einstein and ruxolitinib |
| Q41138516 | JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms |
| Q38684435 | JAK2 inhibitors for myeloproliferative neoplasms: what is next? |
| Q38195778 | Jak-2 positive myeloproliferative neoplasms |
| Q35735663 | Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis |
| Q24186554 | Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis |
| Q51733623 | Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. |
| Q40742224 | Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. |
| Q64116751 | Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis |
| Q41836418 | Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes |
| Q39232415 | Management of myelofibrosis: JAK inhibition and beyond |
| Q28073296 | Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors |
| Q33432406 | Managing patients with myelofibrosis and low platelet counts |
| Q91587430 | Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib |
| Q54250506 | Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis. |
| Q37548944 | Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes |
| Q55063223 | Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor. |
| Q28081693 | Novel therapies for myelofibrosis |
| Q33411763 | Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing |
| Q26750696 | Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib |
| Q38590232 | Pacritinib: a new agent for the management of myelofibrosis? |
| Q37034988 | Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis |
| Q51696636 | Recurrent hypoxemic respiratory failure. Beyond the usual suspects. |
| Q38341625 | Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors |
| Q26738514 | Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned |
| Q92528596 | Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation |
| Q54320183 | Ruxolitinib and survival improvement in patients with myelofibrosis. |
| Q38938939 | Ruxolitinib dose management as a key to long-term treatment success |
| Q37216367 | Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis |
| Q39554738 | Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence |
| Q64973462 | Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management. |
| Q33419865 | Ruxolitinib: a review of its use in patients with myelofibrosis |
| Q33417217 | Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms |
| Q49580473 | SOHO State-of-the-Art Update and Next Questions: MPN. |
| Q38202556 | STAT3 inhibitors: finding a home in lymphoma and leukemia |
| Q38791273 | Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor? |
| Q38267888 | Structural genomic alterations in primary mediastinal large B-cell lymphoma |
| Q49887981 | Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia. |
| Q38297507 | Targeting novel signaling pathways for resistant acute myeloid leukemia |
| Q33443246 | The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation |
| Q33435178 | The development, safety and efficacy of pacritinib for the treatment of myelofibrosis. |
| Q36091279 | The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis |
| Q42335807 | The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies |
| Q35841839 | The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms |
| Q55043645 | The use of JAK inhibitors for low-risk myelofibrosis. |
| Q35988523 | Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase |
| Q54981699 | Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics. |
| Q50453985 | Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. |
| Q40453557 | Usefulness of Low-Dose Splenic Irradiation prior to Reduced-Intensity Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Elderly Patients with Myelofibrosis. |
| Q38774457 | Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera? |
Search more.